Deksanabinol

Deksanabinol
(IUPAC) ime
	(6aS,10aS)-9-(Hidroksimetil)- 6,6-dimetil- 3-(2-metiloktan-2-il)- 6a,7,10,10a-tetrahidrobenzo [c]hromen-1-ol
Klinički podaci
Identifikatori
CAS broj	112924-45-5
ATC kod	nije dodeljen
PubChem	107778
ChemSpider	96934
UNII	R6VT8U5372
Hemijski podaci
Formula	C25H38O3
Mol. masa	386,567 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1 ; Key: SSQJFGMEZBFMNV-PMACEKPBSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Deksanabinol (HU-211, ETS2101^[4]) je sintetički kanabinoidni derivat koji je „neprirodni“ enantiomer potentnog kanabinoidnog agonista HU-210.^[5] Za razliku od kanabinoidnih derivata, HU-211 ne deluje kao agonist kanabinoidnog receptora, nego kao NMDA antagonist.^[6] On stoga ne proizvodi kanabisu slične efekte, ali je antikonvulsant i neuroprotektivan, te nalazi široku primenu u naučnim istraživanjima. On se takođe izučava za moguću primenu u tretmanu povrede glave, moždanog udara i kancera.^[7]^[8]^[9] Klinička istraživanja su pokazala da je bezbedan.^[10]^[11]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ e-therapeutics Clinical Development Pipeline
↑ Pop E (September 2000). „Nonpsychotropic synthetic cannabinoids”. Current Pharmaceutical Design 6 (13): 1347–60. DOI:10.2174/1381612003399446. PMID 10903397.
↑ Feigenbaum JJ, et al. (December 1989). „Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker”. Proceedings of the National Academy of Sciences of the United States of America 86 (23): 9584–7. DOI:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.
↑ Biegon A; Joseph AB (August 1995). „Development of HU-211 as a neuroprotectant for ischemic brain damage”. Neurological Research 17 (4): 275–80. PMID 7477742.
↑ Darlington CL (October 2003). „Dexanabinol: a novel cannabinoid with neuroprotective properties”. IDrugs : the Investigational Drugs Journal 6 (10): 976–9. PMID 14534855.
↑ Vink R; Nimmo AJ (January 2009). „Multifunctional drugs for head injury”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 28–42. DOI:10.1016/j.nurt.2008.10.036. PMID 19110197.
↑ Maas AI, et al. (January 2006). „Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial”. Lancet Neurol 5 (1): 38–45. DOI:10.1016/S1474-4422(05)70253-2. PMID 16361021.
↑ University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.

Spoljašnje veze[uredi | uredi kod]

	Portal Medicina
	Portal Hemija

Šablon:Kanabinoidi

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[e-th-4] -therapeutics Clinical Development Pipeline

[pmid10903397-5] Pop E (September 2000). „Nonpsychotropic synthetic cannabinoids”. Current Pharmaceutical Design 6 (13): 1347–60. DOI:10.2174/1381612003399446. PMID 10903397.

[pmid2556719-6] Feigenbaum JJ, et al. (December 1989). „Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker”. Proceedings of the National Academy of Sciences of the United States of America 86 (23): 9584–7. DOI:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719.

[pmid7477742-7] Biegon A; Joseph AB (August 1995). „Development of HU-211 as a neuroprotectant for ischemic brain damage”. Neurological Research 17 (4): 275–80. PMID 7477742.

[pmid14534855-8] Darlington CL (October 2003). „Dexanabinol: a novel cannabinoid with neuroprotective properties”. IDrugs : the Investigational Drugs Journal 6 (10): 976–9. PMID 14534855.

[pmid19110197-9] Vink R; Nimmo AJ (January 2009). „Multifunctional drugs for head injury”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 28–42. DOI:10.1016/j.nurt.2008.10.036. PMID 19110197.

[pmid16361021-10] Maas AI, et al. (January 2006). „Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial”. Lancet Neurol 5 (1): 38–45. DOI:10.1016/S1474-4422(05)70253-2. PMID 16361021.

[11] University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

Deksanabinol

Reference[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Navigacija

Pretraga